Advanced gastric cancer
Conditions
Interventions
5-FU/Left folic acid (Zuoyu ) First line treatment group of the plan:Simultaneous infusion of Left folic acid and 5-FU
Sponsors
Jiangnan University Affiliated Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male or female, aged 18-75 years old; 2. Patients with unresectable or metastatic gastric cancer confirmed by histopathology have not received chemotherapy or targeted treatment for unresectable or metastatic lesions in the past; 3. At least one measurable lesion according to RECIST 1.1 standard; 4. ECOG PS score: 0-2 points; 5. The expected survival period is greater than 3 months; 6. Patients with normal main organ function and no severe abnormalities in blood, heart, lung, liver, kidney, bone marrow, etc. Laboratory tests meet the following requirements: (1) Hemoglobin (Hb) = 90 g/L; (2) White blood cells (WBC) = 3.0 × 109/L; Neutrophil count (NEUT) = 1.5 × 109/L; (3) Platelet (PLT) = 100 × 109/L (4) Liver function (AST or ALT) level = 2.5 times the upper limit of normal value (ULN); Renal function (serum creatinine sCr) level = 1.5 times the upper limit of normal value (ULN); (5) Total bilirubin (TBIL) = 1.5 times the upper limit of normal value (ULN). 7. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up; Researchers believe that treatment can benefit.
Exclusion criteria
Exclusion criteria: If a patient meets any of the following conditions, they will not be allowed to enter this study: 1 Individuals who have been confirmed to be allergic to the investigational drug and/or its excipients; 2. Subjects who have received or are currently receiving additional chemotherapy, radiation therapy, targeted or immunotherapy; 3. Pregnant or lactating women; 4. Patients who, according to the judgment of the researchers, are not suitable for inclusion in this study; 5. Patients with systemic internal medicine and psychiatric disorders who are not suitable for chemotherapy; 6. Patients who have participated in clinical trials of other drugs within four weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;safety; | — |
Countries
CHINA
Contacts
Public ContactYong Mao
Jiangnan University Affiliated Hospital
Outcome results
None listed